News

Article

Croda Completes Global EXCiPACT Accreditation

The company is the first multi-site excipient supplier to achieve accreditation across production facilities.

Croda announced that all its global excipient manufacturing sites have completed EXCiPACT audit requirements and have been certified according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. The certifications are given after manufacturing processes, quality systems, quality management, and storage and distribution facilities are inspected during audits.

"This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda's compliance to the demanding standards of the pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards," said Dave Cherry, managing director of Croda’s Health Care business, in a press statement.

Source: Croda 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content